Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

S100 Protein Family and Tumorigenesis

S100 Protein Family and Tumorigenesis

 

Geetha Srikrishna and Hudson H. Freeze

Sanford Children's Health Research Center,
Sanford-Burnham Medical Research Institute, La Jolla, California

Correspondence to:
Geetha Srikrishna,
Sanford-Burnham Medical Research Institute,
10905 Road to the Cure, San Diego, CA 92121.
Phone: 858-795-5256: Fax: 858-713-6281:
Email: gsrikrishna@sanfordburnham.org

 

January 2011

 

 

 

1. Introduction

S100 proteins are a family of 25 homologous intracellular calcium-binding proteins characterized by EF hand motifs, low molecular weights (9-13 kDa), ability to form homodimers, heterodimers and oligomeric assemblies, and are characterized by tissue and cell-specific expression (Donato, 2001; Heizmann et al., 2002; Marenholz et al., 2004; Roth et al., 2003) (Figure 1). They are solely present in vertebrates (Donato, 2001). While human S100B, S100P, S100Z and S100G are located at 21q22, 4p16, 5q14 and Xp22 respectively, 21 of the human S100 genes (S100A1-S100A18, trichohyalin, filaggrin and repetin) are clustered at the chromosomal region 1q21, a region that is frequently deleted, translocated or duplicated in epithelial tumors and tumors of soft tissues (Craig et al., 1994; Donato, 2001; Gebhardt et al., 2006; Heizmann et al., 2002) (Figure 2). There is growing evidence that expression of S100 proteins is altered in many tumors, often in association with tumor progression, and they are therefore potentially important tumor biomarkers and therapeutic targets. However, their precise roles in tumor progression are not completely understood.

Figure 1. Dimer structure of S100 proteins. S100 proteins form a large multi-gene family of low molecular weight proteins that are characterized by calcium-binding EF hand motifs and exhibit remarkable tissue and cell-specific expression. They exist as homo and heterodimers, and oligomers. Each monomer consists of two EF-hands connected by a hinge region. (Reproduced from Heizmann CW, Fritz G, Schafer BW. Frontiers in Bioscience. 2002 May 1;7:d1356-68).

Figure 2. The S100 gene cluster on human chromosome 1q21. Most human S100 genes are located in the epidermal differentiation complex on chromosome 1q21, a region prone to rearrangements. Genes located in the cluster region are indicated, as well as two commonly used genomic markers (D1S1664 and D1S2346). p and q indicate the short and the long arm of the chromosome, respectively. Human S100B, S100P, S100Z and S100G are located on chromosomes 21q22, 4p16, 5q14 and Xp22 respectively. (Reproduced from Heizmann CW, Fritz G, Schafer BW. Frontiers in Bioscience. 2002 May 1;7:d1356-68).

2. Structure and functions of S100 proteins

S100 proteins have two distinct EF-hand (helix-loop-helix motif) calcium-binding domains connected by a hinge region (Fritz et al., 2010). The canonical C-terminal calcium-binding EF- hand is common to all EF-hand proteins, while the N-terminal EF-hand is non-canonical. There is variable degree of sequence identity among S100 proteins. S100 proteins exist as anti-parallel hetero and homodimers within cells. Calcium binding causes conformational changes that exposes binding sites for target proteins.
Intracellular functions of S100 proteins have been extensively studied. These include calcium homeostasis, cell cycle regulation, cell growth and migration, cytoskeletal interactions, membrane trafficking, protein phosphorylation, and regulation of transcriptional factors among others (Donato, 2001; Heizmann et al., 2002; Marenholz et al., 2004; Roth et al., 2003). S100 proteins can also be released into extracellular space in response to stimuli, or during cell damage, and they promote responses including neuronal survival and extension (S100B), apoptosis (S100A4 and S100A6), inflammation (S100B, S100A8/A9, S100A11 and S100A12), autoimmunity (S100A8/A9), chemotaxis (S100A8/A9) and cell proliferation and survival (S100P, S100A7), thus effectively functioning as paracrine and autocrine mediators. S100B, S100P, S100A4, S100A6, S100A8/A9, S100A11 and S100A12 are known to act via interaction with cell surface receptors, primarily the Receptor for Advanced Glycation End Products (RAGE) (Donato, 2007; Leclerc et al., 2009), while S100A8/A9 also bind Toll-like receptors or TLRs (Vogl et al., 2007). Multimeric forms of S100 proteins appear to be necessary for the extracellular functions of S100 proteins (Donato, 2007; Leukert et al., 2006). Multimeric assemblies have been reported for S100A12, S100A4, S100B and S100A8/A9 (Fritz et al., 2010). Elevated S100 protein levels are associated with chronic inflammation, neurodegeneration, cardiomyopathies, atherosclerosis and cancer (Pietzsch, 2010).

3. S100 proteins and tumorigenesis

A number of S100 proteins are up-regulated in tumors (Salama et al., 2008). With the identification of binding proteins and signaling pathways for at least a few of its family members, S100 proteins promise to offer both functional biomarkers and therapeutic targets in cancers, and the case for considering their importance is evolving rapidly (summarized in Table 1).

Table 1. Expression of S100 proteins in tumors*.
S100 proteins Tumors in which expression is up-regulated Tumors in which expression is down-regulated Known functions / interactions / mechanism of action
S100A1
  • Renal, clear cell and papillary
  • Endometriod subtype of ovarian and endometrial
  Known RAGE ligand.
S100A2
  • Lung, non-small cell
  • Pancreatic
  • Gastric
  • Thyroid, papillary and anaplastic
  • Oral squamous cell
  • Prostate
Promotes p53 transcriptional activity and reduces expression of Cox-2.
S100A4
  • Breast
  • Colorectal
  • Gastric
  • Prostate
  • Lung, non-small cell
  • Ovarian
  • Pancreatic
  • Melanoma
  Promotes tumor migration, invasion and angiogenesis. Regulates matrix metalloproteinases and interacts with p53 and inhibits p53 phosphorylation.
S100A6
  • Colorectal
  • Pancreatic
  • Gastric
  • Hepatocellular
  • Lung
  • Melanoma
  Known RAGE ligand.
S100A7
  • Breast, ER negative invasive, DCIS
  • Bladder
  • Skin
  Possible interaction with Jab-1.
S100A8/A9
  • Gastric
  • Colon
  • Pancreatic
  • Bladder
  • Ovarian
  • Thyroid
  • Breast
  • Skin
  Interaction with RAGE and TLR4; promote tumor proliferation, and migration, accumulation of myeloid derived suppressor cells, activation of protumorigenic genes, and formation of premetastatic niches in distal organs.
S100A11
  • Uterine, smooth muscle
  • Lymphoma, anaplastic large cell
  • Pancreatic
  • Bladder
  • Esophageal, squamous cell
 
S100B
  • Melanoma (biomarker)
  • Astrocytoma, anaplastic
  • Glioblastomas
  Interacts with p53 and down-regulates p53-mediated apoptosis in melanoma. Well known RAGE ligand.
S100P
  • Ovarian
  • Pancreatic
  • Breast
  • Gastric
  • Colorectal
  • Prostate
  • Lung
  Activation of RAGE dependent signaling pathways.

* Relevant references are provided in the text.

3.1. S100A1

S100A1 is predominantly expressed in the heart, and to a lesser extent in the skeletal muscle (Heizmann et al., 2007; Leclerc et al., 2009). S100A1 is a key modulator of calcium homeostasis in the heart and targets several key regulators of sarcoplasmic reticulum including Ca2+ ATPase, ryanodine receptors and other targets, thereby enhancing cardiomyocyte performance. Dysregulation of cardiomyocyte S100A1 protein, and diminished levels following myocardial infarction contributes to cardiac hypertrophy and heart failure. Extracellularly, S100A1 exists as both a homodimer and heterodimer with S100B, S100A4 and S100P and interacts with RAGE (Leclerc et al., 2009).
Besides cardiac and skeletal muscle, expression of S100A1 is low in most normal tissues, but up-regulated in cancers of the kidneys, skin and ovary. S100A1 expression helps to differentiate subtypes of renal carcinoma. S100A1 protein is expressed in renal oncocytomas, and in clear cell and papillary renal cell carcinomas but not in chromophobe renal cell carcinomas (Cossu-Rocca et al., 2009; Li et al., 2007). In addition, S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma where it is not expressed (Cossu-Rocca et al., 2009). S100A1 messenger RNA and protein are up-regulated in ovarian tumors and ovarian cancer metastasis compared with normal ovarian tissues. In the endometrioid subtype of ovarian and endometrial cancers, there is a negative correlation between relapse-free survival and S100A1 expression, suggesting that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer (DeRycke et al., 2009).

3.2. S100A2

S100A2 protein is present in many organs or tissues, with high expression in lung and kidney. Unlike most other S100 proteins, S100A2 is markedly down-regulated in many tumors suggesting that it acts as a tumor suppressor gene. It promotes transcriptional activity of p53 (Mueller et al., 2005) and reduces expression of Cox-2 (Tsai et al., 2006). On the other hand, S100A2 is also up-regulated in some tumors (Salama et al., 2008; Wolf et al., 2010).
Loss of S100A2 expression has been associated with poor prognosis and shorter survival. S100A2 expression decreases in epithelial cells from normal to tumor stages, with the decrease more pronounced in glandular than in squamous epithelial tissue (Nagy et al., 2002). S100A2 expression is reduced in early-stage oral squamous cell carcinoma and is significantly associated with tumor recurrence and metastasis (Suzuki et al., 2005; Tsai et al., 2005). Patients with S100A2 positive laryngeal squamous cell carcinoma had a better relapse-free overall survival than patients with S100A2-negative tumors (Almadori et al., 2009). Benign prostate hyperplasia and prostatitis are characterized by higher levels of S100A2 than low-grade cancer, and expression is lost in high-grade and metastatic cancer specimens (Gupta et al., 2003).
S100A2 is up-regulated in some tumors such as non-small cell lung carcinoma (Smith et al., 2004), with higher expression found in early-stage carcinomas, associated with reduced overall survival, and higher propensity to metastasis (Bartling et al., 2007; Bulk et al., 2009; Feng et al., 2001; Wang et al., 2005; Zech et al., 2006). In pancreatic cancer tissues and cell lines, S100A2 expression is significantly higher than in normal pancreatic tissues, and higher expression co-related with poor disease outcome (Biankin et al., 2009; Ohuchida et al., 2007). S100A2 is also over-expressed in gastric tumors compared to normal gastric mucosa (Lee et al., 2006). Varied expression has been reported with oesophageal squamous carcinoma (Cao et al., 2009; Imazawa et al., 2005; Ji et al., 2004). In thyroid carcinomas, S100A2 is absent in follicular adenomas and carcinomas, but up-regulated in papillary and anaplastic carcinomas, providing a possible marker for distinguishing these two types of thyroid carcinoma (Ito et al., 2005).

3.3. S100A4

S100A4, also called Metastatin due to its well-established association with tumor metastasis (Tarabykina et al., 2007; Sherbet, 2009; Boye and Maelandsmo, 2010), is normally found in the nervous system and believed to be involved in neuritogenesis. S100A4 is also expressed at low levels in normal human fibroblasts, monocytes, macrophages, T cells, neutrophils, and endothelial cells. Although its expression is low in normal tissues, it is highly expressed in many tumors such as breast, colorectal, gastric, prostate and non-small cell lung cancer, ovarian and pancreatic cancers, and malignant melanoma (Boye and Maelandsmo, 2010; Sherbet, 2009). Expression is a significant predictor of patient survival and metastatic disease. S100A4 was first cloned from highly metastatic breast cancer cells, and since then its involvement in cancer metastasis has been substantiated by several studies (Boye and Maelandsmo, 2010; Sherbet, 2009; Tarabykina et al., 2007). Studies show that extracellular, intracellular, tumor-derived, and stroma-derived S100A4 all contribute to the metastatic process, and influence several steps in the metastatic cascade, including migration, invasion, and angiogenesis. Much of this metastatic potential has been linked to the ability of S100A4 to regulate matrix metalloproteinases, modulate cell motility, promote angiogenesis and epithelial mesenchymal transition, and the association of S100A4 expression with reduced expression of tumor suppressor genes such as p53 (Garrett et al., 2006; Salama et al., 2008). S100A4 interacts with p53 and inhibits p53-mediated tumor suppression by inhibiting its phosphorylation (Grigorian et al., 2001). The extensive association of S100A4 with tumor progression and metastasis has positioned it to be a target for novel therapeutic strategies.

3.4. S100A6

S100A6 is highly expressed in various organs, and on fibroblasts, epithelial and other cells (Leclerc et al., 2009; Lesniak et al., 2009). S100A6 is predominantly cytoplasmic protein but can translocate in the presence of Ca2+ to plasma membrane and the nuclear envelope. S100A6 expression can be up-regulated by platelet-derived growth factor, epidermal growth factor, tumor necrosis factor, retinoic acid and estrogen, and upon stress conditions, and at the transcriptional level by NF-κB. S100A6 interacts with many proteins including CacyBP/SIP, annexins II and XI, tropomycin and RAGE (Leclerc et al., 2009; Lesniak et al., 2009). S100A6 is overexpressed in many cancers including colorectal, pancreatic, gastric, hepatocellular and lung cancers, and melanoma. Expression in melanoma, pancreatic and colorectal cancers has been shown to correlate with tumor growth and metastatic progression suggesting a potential role for S100A6 in the development of malignancy (Lesniak et al., 2009; Salama et al., 2008). It is however down-regulated in prostate cancer and medulloblastoma.

3.5. S100A7

S100A7 was first identified in inflamed psoriatic skin, hence is also called psoriasin (Watson et al., 1998). It is released from keratinocytes around wounds and believed to exert cytokine and anti bacterial effects, and is also chemotactic for granulocyes, monocytes and lymphocytes (Eckert et al., 2004). Contrary to other S100 proteins, calcium binding does not induce large conformational changes in S100A7 (Streicher et al., 2010). S100A7 is up regulated in breast, bladder and skin cancers (Salama et al., 2008). Increasing evidence show that S100A7 is up-regulated in ductal carcinoma in situ and ER negative invasive breast cancer and expression correlates with aggressive phenotype and patient survival (Emberley et al., 2004b). S100A7 interacts with Jab1 (c-jun activation domain binding protein 1) a protein with highly recognizable role in tumorigenesis to elicit functional effects in breast tumor progression (Emberley et al., 2004a).

3.6. S100A8/A9

S100A8 and S100A9 are expressed predominantly by myeloid cells, including granulocytes, monocytes, myeloid derived suppressor cells (MDSC) and other immature cells of myeloid lineage (Cheng et al., 2008; Goyette and Geczy, 2010; Roth et al., 2003; Sinha et al., 2008). Although the proteins are products of distinct genes, they are often co-expressed and function mainly as heterodimer of S100A8/A9 (calprotectin). Expression is down-regulated during macrophage and dendritic cell differentiation (Cheng et al., 2008; Lagasse and Clerc, 1988; Odink et al., 1987), but can be induced in epithelial cells, osteoclasts and keratinocytes (Gebhardt et al., 2006). S100A8/A9 released into the extracellular medium in response to cell damage or activation become danger signals (Damage Associated Molecular Pattern molecules or DAMP), which alert the host of danger by triggering immune responses and activating repair mechanisms through interaction with pattern recognition receptors (Donato, 2007; Ehrchen et al., 2009; Foell et al., 2007; Leclerc et al., 2009; Srikrishna and Freeze, 2009). Elevated S100A8/A9 is the hallmark of inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, cystic fibrosis and psoriasis (Foell et al., 2007; Roth et al., 2001; Roth et al., 2003). Critical roles for these proteins in endotoxin-induced lethality and systemic autoimmunity have recently been recognized (Loser et al., 2010; Vogl et al., 2007). In addition to expression within inflammatory milieu, strong up-regulation of these proteins has also been observed in many tumors, including gastric, colon, pancreatic, bladder, ovarian, thyroid, breast and skin cancers (Gebhardt et al., 2006; Salama et al., 2008).
S100A8/A9 exhibit concentration-dependent dichotomy of function in tumors. At high concentrations S100A8/A9 exert apoptotic effects on tumor cells (Ghavami et al., 2004), while at low concentrations promote tumor cell growth (Ghavami et al., 2008; Turovskaya et al., 2008). S100A8/A9 also stimulate tumor cell migration at low concentrations (Ang et al., 2010; Hermani et al., 2006; Hiratsuka et al., 2006; Moon et al., 2008; Saha et al., 2010). S100A8/A9 regulate the accumulation of MDSC (Cheng et al., 2008; Sinha et al., 2008), which are immature myeloid cells that expand during inflammation and in tumors, and are potent suppressors of T-cell mediated immune responses (Dolcetti et al., 2008; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009). Tumor derived factors promote sustained STAT3 dependent upregulation of S100A9 in myeloid precursors which results in inhibition of differentiation to DC and accumulation of MDSC (Cheng et al., 2008). S100A8/A9 are not only synthesized and secreted by MDSC, but they also have binding sites for S100A8/A9, and activate intracellular signaling that promote their migration (Sinha, et al., 2008), suggesting that S100A8/A9 support an autocrine feedback loop that sustains accumulation of MDSC in tumors (Ostrand-Rosenberg, 2008). They also bind to tumor cells and activate MAPK and NF-κB signaling pathways and specific downstream genes that promote tumorigenesis (Ghavami et al., 2009; Ichikawa et al., 2011). S100A8/A9 are involved in early metastatic processes. Expression of S100A8/A9 in myeloid and endothelial cells in premetastatic organs in response to soluble factors such as VEGF, TGFβ and TNFα expressed by distal primary tumors promotes homing of tumor cells to premetastatic niches (Hiratsuka et al., 2006). Recent studies argue for prominent roles for two pattern recognition receptors, TLR4 and RAGE, in S100A8/A9 mediated pathological effects (Gebhardt et al., 2008; Loser et al., 2010; Sinha et al., 2008; Turovskaya et al., 2008; Vogl et al., 2007).

3.7. S100A11

S100A11, also called S100C or calgizzarin, is expressed in many tissues including the placenta, heart, lung, and kidney (He et al., 2009; Inada et al., 1999; Salama et al., 2008). Expression levels are low in skeletal muscle and liver (Inada et al., 1999). S100A11 is overexpressed in uterine smooth muscle tumors (Kanamori et al., 2004), anaplastic large cell lymphomas (Rust et al., 2005), and pancreatic tumors (Ohuchida et al., 2006b), while significantly down-regulated in esophageal squamous cell (Ji et al., 2004) and bladder tumors (Memon et al., 2005). In bladder carcinoma, down-regulation of S100A11 is associated with poor prognosis and decreased survival, suggesting that S100A11 functions as a tumor suppressor (Memon et al., 2005). In pancreatic cancer, S100A11 is over-expressed in early stages and down-regulated in advanced tumors, again supporting a tumor-suppressor role and suggesting that S100A11 expression could be valuable in detecting early pancreatic tumors (Ohuchida et al., 2006b). On the other hand, S100A11 expression in prostate cancer is associated with advanced disease (Rehman et al., 2004), showing that S100A11 plays opposing roles depending on the tumor involved.

3.8. S100B

S100B is one of the best-studied proteins of the S100 family and its interaction with RAGE has been well characterized (Donato, 2007; Donato et al., 2008; Leclerc et al., 2009). S100B is particularly abundant in the brain and is highly expressed by astrocytes, oligodendrocytes and Schwann cells. It is considered as an intracellular regulator and extracellular signal, exerting concentration-dependent trophic as well as toxic effects on neurons (Donato et al., 2008). It also activates microglia, and may have a role in the pathogenesis of neurodegenerative disorders. S100B is over-expressed in anaplastic astrocytomas and glioblastomas (Camby et al., 1999), and melanomas (Salama et al., 2008). S100B interacts with p53 in melanomas and down-regulates p53 mediated apopotosis (Lin et al., 2010). S100B is the best-studied biomarker for melanoma (Gogas et al., 2009; Salama et al., 2008). Serum levels of S100B increases in a stage-dependent manner in patients with melanoma, reflecting tumor load, with decline during therapy and remission, and correlate well with overall survival. Elevated levels following therapy has shown to correlate with melanoma recurrence. S100B is thus the first of the S100 proteins to be validated in a clinical setting.

3.9. S100P

S100P was first purified from placenta, but it is also expressed in many normal tissues including the GI tract, and in prostate and leukocytes (Arumugam and Logsdon, 2010; Leclerc et al., 2009). S100P is also expressed in many tumors, including ovarian, pancreatic, breast, gastric, colorectal, prostate, and lung carcinomas, and has been shown to be associated with poor clinical outcomes (Arumugam and Logsdon, 2010; Leclerc et al., 2009). Recent studies implicate DNA hypomethylation, bone morphogenic protein and non-steroidal anti-inflammatory drugs in the regulation of S100P expression in tumors (Hamada et al., 2009; Namba et al., 2009; Sato et al., 2004). S100P is expressed in pancreatic cancer cells, but not in pancreatic inflammation, and is also elevated early in preneoplastic cells, suggesting that S100P may be a useful biomarker for pancreatic cancer (Logsdon et al., 2003; Ohuchida et al., 2006a). S100P is absent in normal breast tissue but detected in hyperplasia, as well as in situ and invasive ductal carcinoma (Guerreiro Da Silva et al., 2000). Immunochemical studies show correlation between S100P and estrogen receptor expression, and with high-risk lesions and decreased survival (Schor et al., 2006). S100P has been shown to induce breast cancer metastasis (Wang et al., 2006). S100P is also up-regulated in colon cancer cells (Bertram et al., 1998; Fuentes et al., 2007), and in flat adenomas in the colon (Kita et al., 2006). S100P can be secreted, and interacts with RAGE on pancreatic and colon tumor cells (Arumugam et al., 2005; Fuentes et al., 2007), activating NF-κB and MAPK pathways (Fuentes et al., 2007). Efforts are therefore underway to develop small molecule inhibitors that block the interaction of S100P and RAGE.

Summary

There is growing evidence that many S100 proteins are altered in human tumors. Future studies are likely to reveal molecular mechanisms that define the multiple and specific roles that S100 proteins play in tumor progression and metastasis, providing novel therapeutic targets and biomarkers.

Bibliography

Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis.
Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G, Schlegel R, Sorg C.
Nature. 1987 Nov 5-11;330(6143):80-2.
PMID 3313057
 
Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation.
Lagasse E, Clerc RG.
Mol Cell Biol. 1988 Jun;8(6):2402-10.
PMID 3405210
 
Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats.
Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I.
Brain Res. 1991 Sep 20;559(2):233-40.
PMID 1794099
 
Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease.
Craig RW, Jabs EW, Zhou P, Kozopas KM, Hawkins AL, Rochelle JM, Seldin MF, Griffin CA.
Genomics. 1994 Sep 15;23(2):457-63.
PMID 7835896
 
Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression.
Bertram J, Palfner K, Hiddemann W, Kneba M.
Anticancer Drugs. 1998 Apr;9(4):311-7.
PMID 9635921
 
Psoriasin (S100A7).
Watson PH, Leygue ER, Murphy LC.
Int J Biochem Cell Biol. 1998 May;30(5):567-71. (REVIEW)
PMID 9693957
 
Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins.
Camby I, Nagy N, Lopes MB, Schafer BW, Maurage CA, Ruchoux MM, Murmann P, Pochet R, Heizmann CW, Brotchi J, Salmon I, Kiss R, Decaestecker C.
Brain Pathol. 1999 Jan;9(1):1-19.
PMID 9989446
 
Human S100A11 exhibits differential steady-state RNA levels in various tissues and a distinct subcellular localization.
Inada H, Naka M, Tanaka T, Davey GE, Heizmann CW.
Biochem Biophys Res Commun. 1999 Sep 16;263(1):135-8.
PMID 10486266
 
S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo.
Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, Russo J.
Int J Oncol. 2000 Feb;16(2):231-40.
PMID 10639564
 
S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.
Donato R.
Int J Biochem Cell Biol. 2001 Jul;33(7):637-68. (REVIEW)
PMID 11390274
 
Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
Feng G, Xu X, Youssef EM, Lotan R.
Cancer Res. 2001 Nov 1;61(21):7999-8004.
PMID 11691825
 
Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction.
Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N, Christensen A, Selivanova G, Lukanidin E.
J Biol Chem. 2001 Jun 22;276(25):22699-708. Epub 2001 Mar 5.
PMID 11278647
 
S100A8 and S100A9 in inflammatory diseases.
Roth J, Goebeler M, Sorg C.
Lancet. 2001 Mar 31;357(9261):1041.
PMID 11293617
 
S100 proteins: structure, functions and pathology.
Heizmann CW, Fritz G, Schafer BW.
Front Biosci. 2002 May 1;7:d1356-68. (REVIEW)
PMID 11991838
 
The Ca2+-binding S100A2 protein is differentially expressed in epithelial tissue of glandular or squamous origin.
Nagy N, Hoyaux D, Gielen I, Schafer BW, Pochet R, Heizmann CW, Kiss R, Salmon I, Decaestecker C.
Histol Histopathol. 2002 Jan;17(1):123-30.
PMID 11813862
 
Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.
Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H.
J Clin Oncol. 2003 Jan 1;21(1):106-12.
PMID 12506178
 
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.
Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S.
Cancer Res. 2003 May 15;63(10):2649-57.
PMID 12750293
 
Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules.
Roth J, Vogl T, Sorg C, Sunderkotter C.
Trends Immunol. 2003 Apr;24(4):155-8. (REVIEW)
PMID 12697438
 
S100 proteins in the epidermis.
Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K.
J Invest Dermatol. 2004 Jul;123(1):23-33. (REVIEW)
PMID 15191538
 
S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.
Breast Cancer Res. 2004a;6(4):R308-15. Epub 2004 Apr 26.
PMID 15217497
 
S100A7 and the progression of breast cancer.
Emberley ED, Murphy LC, Watson PH.
Breast Cancer Res. 2004b;6(4):153-9. Epub 2004 Jun 4. (REVIEW)
PMID 15217486
 
Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions.
Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F.
J Leukoc Biol. 2004 Jul;76(1):169-75. Epub 2004 Apr 1.
PMID 15075348
 
Differential expression of S100 gene family in human esophageal squamous cell carcinoma.
Ji J, Zhao L, Wang X, Zhou C, Ding F, Su L, Zhang C, Mao X, Wu M, Liu Z.
J Cancer Res Clin Oncol. 2004 Aug;130(8):480-6. Epub 2004 Jun 4.
PMID 15185146
 
Increased expression of calcium-binding protein S100 in human uterine smooth muscle tumours.
Kanamori T, Takakura K, Mandai M, Kariya M, Fukuhara K, Sakaguchi M, Huh NH, Saito K, Sakurai T, Fujita J, Fujii S.
Mol Hum Reprod. 2004 Oct;10(10):735-42. Epub 2004 Aug 20.
PMID 15322223
 
S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature).
Marenholz I, Heizmann CW, Fritz G.
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22. (REVIEW)
PMID 15336958
 
Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, Larre S, Champigneuille J, Hamdy FC.
Hum Pathol. 2004 Nov;35(11):1385-91.
PMID 15668896
 
Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.
Sato N, Fukushima N, Matsubayashi H, Goggins M.
Oncogene. 2004 Feb 26;23(8):1531-8.
PMID 14716296
 
S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK, Betticher DC, Heighway J.
Br J Cancer. 2004 Oct 18;91(8):1515-24.
PMID 15467767
 
S100P promotes pancreatic cancer growth, survival, and invasion.
Arumugam T, Simeone DM, Van Golen K, Logsdon CD.
Clin Cancer Res. 2005 Aug 1;11(15):5356-64.
PMID 16061848
 
S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma.
Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S, Nakao A.
Anticancer Res. 2005 Mar-Apr;25(2B):1247-50.
PMID 15865073
 
Expression of S100A2 and S100A6 in thyroid carcinomas.
Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A.
Histopathology. 2005 May;46(5):569-75.
PMID 15842639
 
Down-regulation of S100C is associated with bladder cancer progression and poor survival.
Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):606-11.
PMID 15701847
 
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity.
Mueller A, Schafer BW, Ferrari S, Weibel M, Makek M, Hochli M, Heizmann CW.
J Biol Chem. 2005 Aug 12;280(32):29186-93. Epub 2005 Jun 7.
PMID 15941720
 
High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma.
Rust R, Visser L, van der Leij J, Harms G, Blokzijl T, Deloulme JC, van der Vlies P, Kamps W, Kok K, Lim M, Poppema S, van den Berg A.
Br J Haematol. 2005 Dec;131(5):596-608.
PMID 16351635
 
S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity.
Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K, Yamaguchi S, Furuta Y, Fukuda S.
Oncol Rep. 2005 Dec;14(6):1493-8.
PMID 16273244
 
S100A2, a potential marker for early recurrence in early-stage oral cancer.
Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC, Chang MT, Wu LW.
Oral Oncol. 2005 Apr;41(4):349-57.
PMID 15792606
 
Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer.
Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP, Katz RL, Jiang F.
Int J Cancer. 2005 Aug 20;116(2):285-90.
PMID 15800916
 
S100A4, a mediator of metastasis.
Garrett SC, Varney KM, Weber DJ, Bresnick AR.
J Biol Chem. 2006 Jan 13;281(2):677-80. Epub 2005 Oct 21. (REVIEW)
PMID 16243835
 
S100A8 and S100A9 in inflammation and cancer.
Gebhardt C, Nemeth J, Angel P, Hess J.
Biochem Pharmacol. 2006 Nov 30;72(11):1622-31. Epub 2006 Jul 17. (REVIEW)
PMID 16846592
 
S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D.
Exp Cell Res. 2006 Jan 15;312(2):184-97. Epub 2005 Nov 17.
PMID 16297907
 
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
Hiratsuka S, Watanabe A, Aburatani H, Maru Y.
Nat Cell Biol. 2006 Dec;8(12):1369-75. Epub 2006 Nov 26.
PMID 17128264
 
Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis.
Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui ZG, Osawa H, Ohnishi H, Mutoh H, Hoshino H, Bowlus CL, Yamamoto H, Sugano K.
J Gastroenterol. 2006 Nov;41(11):1053-63. Epub 2006 Dec 8.
PMID 17160516
 
Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.
Lee OJ, Hong SM, Razvi MH, Peng D, Powell SM, Smoklin M, Moskaluk CA, El-Rifai W.
Neoplasia. 2006 Oct;8(10):843-50.
PMID 17032501
 
Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity.
Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J.
J Mol Biol. 2006 Jun 16;359(4):961-72. Epub 2006 Apr 21.
PMID 16690079
 
S100P is an early developmental marker of pancreatic carcinogenesis.
Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M.
Clin Cancer Res. 2006a Sep 15;12(18):5411-6.
PMID 17000674
 
S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis.
Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M.
Clin Cancer Res. 2006b Sep 15;12(18):5417-22.
PMID 17000675
 
S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.
Schor AP, Carvalho FM, Kemp C, Silva ID, Russo J.
Oncol Rep. 2006 Jan;15(1):3-6.
PMID 16328027
 
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
Tsai WC, Tsai ST, Jin YT, Wu LW.
Mol Cancer Res. 2006 Aug;4(8):539-47.
PMID 16908593
 
Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.
Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS.
Cancer Res. 2006 Jan 15;66(2):1199-207.
PMID 16424059
 
Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer.
Zech VF, Dlaska M, Tzankov A, Hilbe W.
Cancer Detect Prev. 2006;30(5):395-402. Epub 2006 Oct 25.
PMID 17067748
 
S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy.
Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A.
Eur J Cancer. 2007 Sep;43(13):1935-43. Epub 2007 Aug 3.
PMID 17689067
 
RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins.
Donato R.
Curr Mol Med. 2007 Dec;7(8):711-24. (REVIEW)
PMID 18331229
 
S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.
Foell D, Wittkowski H, Vogl T, Roth J.
J Leukoc Biol. 2007 Jan;81(1):28-37. Epub 2006 Aug 30. (REVIEW)
PMID 16943388
 
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, Huang EH.
Dis Colon Rectum. 2007 Aug;50(8):1230-40.
PMID 17587138
 
Pathologies involving the S100 proteins and RAGE.
Heizmann CW, Ackermann GE, Galichet A.
Subcell Biochem. 2007;45:93-138. (REVIEW)
PMID 18193636
 
S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma.
Li G, Barthelemy A, Feng G, Gentil-Perret A, Peoc'h M, Genin C, Tostain J.
Histopathology. 2007 Apr;50(5):642-7.
PMID 17394501
 
Metastasis-associated protein S100A4: spotlight on its role in cell migration.
Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M.
Curr Cancer Drug Targets. 2007 May;7(3):217-28. (REVIEW)
PMID 17504119
 
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J.
Nat Med. 2007 Sep;13(9):1042-9. Epub 2007 Sep 2.
PMID 17767165
 
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI.
J Exp Med. 2008 Sep 29;205(10):2235-49. Epub 2008 Sep 22.
PMID 18809714
 
Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V.
Cancer Lett. 2008 Aug 28;267(2):216-25. Epub 2008 Apr 22. (REVIEW)
PMID 18433992
 
RAGE signaling sustains inflammation and promotes tumor development.
Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P.
J Exp Med. 2008 Feb 18;205(2):275-85. Epub 2008 Jan 21.
PMID 18208974
 
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.
Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M.
J Leukoc Biol. 2008 Jun;83(6):1484-92. Epub 2008 Mar 13.
PMID 18339893
 
Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion.
Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR.
Mol Cancer Res. 2008 Oct;6(10):1544-53.
PMID 18922970
 
Cancer and complement.
Ostrand-Rosenberg S.
Nat Biotechnol. 2008 Dec;26(12):1348-9.
PMID 19060872
 
A review of the S100 proteins in cancer.
Salama I, Malone PS, Mihaimeed F, Jones JL.
Eur J Surg Oncol. 2008 Apr;34(4):357-64. Epub 2007 Jun 13. (REVIEW)
PMID 17566693
 
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G.
J Immunol. 2008 Oct 1;181(7):4666-75.
PMID 18802069
 
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G.
Carcinogenesis. 2008 Oct;29(10):2035-43. Epub 2008 Aug 9.
PMID 18689872
 
Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma.
Almadori G, Bussu F, Galli J, Rigante M, Lauriola L, Michetti F, Maggiano N, Schafer BW, Heizmann CW, Ranelletti FO, Paludetti G.
J Otolaryngol Head Neck Surg. 2009 Feb;38(1):16-22.
PMID 19344608
 
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, Chang DK, Morey AL, Lee CS, Pinese M, Kuo SC, Susanto JM, Cosman PH, Lindeman GJ, Visvader JE, Nguyen TV, Merrett ND, Warusavitarne J, Musgrove EA, Henshall SM, Sutherland RL; NSW Pancreatic Cancer Network.
Gastroenterology. 2009 Aug;137(2):558-68, 568.e1-11. Epub 2009 Apr 16.
PMID 19376121
 
S100A2 induces metastasis in non-small cell lung cancer.
Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, Kerkhoff C, Gerke V, Liersch R, Mesters RM, Hotfilder M, Marra A, Koschmieder S, Dugas M, Berdel WE, Serve H, Muller-Tidow C.
Clin Cancer Res. 2009 Jan 1;15(1):22-9.
PMID 19118029
 
Expression and clinical significance of S100A2 and p63 in esophageal carcinoma.
Cao LY, Yin Y, Li H, Jiang Y, Zhang HF.
World J Gastroenterol. 2009 Sep 7;15(33):4183-8.
PMID 19725154
 
S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G.
Am J Surg Pathol. 2009 Jul;33(7):1031-6.
PMID 19384190
 
S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
DeRycke MS, Andersen JD, Harrington KM, Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA, Skubitz AP.
Am J Clin Pathol. 2009 Dec;132(6):846-56.
PMID 19926575
 
S100B's double life: intracellular regulator and extracellular signal.
Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I.
Biochim Biophys Acta. 2009 Jun;1793(6):1008-22. Epub 2008 Dec 7. (REVIEW)
PMID 19110011
 
The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.
Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J.
J Leukoc Biol. 2009 Sep;86(3):557-66. Epub 2009 May 18. (REVIEW)
PMID 19451397
 
Myeloid-derived suppressor cells as regulators of the immune system.
Gabrilovich DI, Nagaraj S.
Nat Rev Immunol. 2009 Mar;9(3):162-74. (REVIEW)
PMID 19197294
 
S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis.
Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C.
Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83. Epub 2009 Oct 14. (REVIEW)
PMID 19835859
 
Biomarkers in melanoma.
Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R.
Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13. (REVIEW)
PMID 19617299
 
Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines.
Hamada S, Satoh K, Hirota M, Fujibuchi W, Kanno A, Umino J, Ito H, Satoh A, Kikuta K, Kume K, Masamune A, Shimosegawa T.
Cancer Sci. 2009 Jan;100(1):103-10. Epub 2008 Oct 23.
PMID 19018761
 
S100A11: diverse function and pathology corresponding to different target proteins.
He H, Li J, Weng S, Li M, Yu Y.
Cell Biochem Biophys. 2009;55(3):117-26. Epub 2009 Aug 1. (REVIEW)
PMID 19649745
 
Binding of S100 proteins to RAGE: an update.
Leclerc E, Fritz G, Vetter SW, Heizmann CW.
Biochim Biophys Acta. 2009 Jun;1793(6):993-1007. Epub 2008 Dec 11. (REVIEW)
PMID 19121341
 
S100A6 - new facts and features.
Lesniak W, Slomnicki LP, Filipek A.
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1087-92. Epub 2009 Nov 3. (REVIEW)
PMID 19891957
 
Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects.
Namba T, Homan T, Nishimura T, Mima S, Hoshino T, Mizushima T.
J Biol Chem. 2009 Feb 13;284(7):4158-67. Epub 2008 Dec 10.
PMID 19073601
 
Myeloid-derived suppressor cells: linking inflammation and cancer.
Ostrand-Rosenberg S, Sinha P.
J Immunol. 2009 Apr 15;182(8):4499-506. (REVIEW)
PMID 19342621
 
Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy.
Sherbet GV
Cancer Lett. 2009 Jul 18;280(1):15-30. Epub 2008 Dec 6. (REVIEW)
PMID 19059703
 
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
Srikrishna G, Freeze HH.
Neoplasia. 2009 Jul;11(7):615-28. (REVIEW)
PMID 19568407
 
Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells.
Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I, Khattak I, Azadeh B, Dodson A, Kalirai H, Neoptolemos JP, Rooney PS, Costello E.
Carcinogenesis. 2010 Sep;31(9):1541-51. Epub 2010 Jul 9.
PMID 20622003
 
S100P: a novel therapeutic target for cancer.
Arumugam T, Logsdon CD.
Amino Acids. 2010 May 28. [Epub ahead of print]
PMID 20509035
 
S100A4 and metastasis: a small actor playing many roles.
Boye K, Maelandsmo GM.
Am J Pathol. 2010 Feb;176(2):528-35. Epub 2009 Dec 17. (REVIEW)
PMID 20019188
 
Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity.
Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM.
FEBS J. 2010 Nov;277(22):4578-90. (REVIEW)
PMID 20977662
 
Inflammation-associated S100 proteins: new mechanisms that regulate function.
Goyette J, Geczy CL.
Amino Acids. 2010 Mar 6. [Epub ahead of print]
PMID 20213444
 
The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma.
Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ.
J Biol Chem. 2010 Aug 27;285(35):27487-98. Epub 2010 Jun 29.
PMID 20587415
 
The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells.
Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, Luger TA, Roth J, Beissert S.
Nat Med. 2010 Jun;16(6):713-7. Epub 2010 May 9.
PMID 20473308
 
S100 proteins in health and disease.
Pietzsch J.
Amino Acids. 2010 Dec 1. [Epub ahead of print]
PMID 21120552
 
Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs.
Saha A, Lee YC, Zhang Z, Chandra G, Su SB, Mukherjee AB.
J Biol Chem. 2010 Apr 2;285(14):10822-31. Epub 2010 Jan 29.
PMID 20118237
 
Modulation of quaternary structure of S100 proteins by calcium ions.
Streicher WW, Lopez MM, Makhatadze GI.
Biophys Chem. 2010 Oct;151(3):181-6. Epub 2010 Jun 23.
PMID 20621410
 
S100A2 in cancerogenesis: a friend or a foe?
Wolf S, Haase-Kohn C, Pietzsch J.
Amino Acids. 2010 Jun 3. [Epub ahead of print]
PMID 20521072
 
S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression.
Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G.
Mol Cancer Res. 2011 Feb;9(2):133-48. Epub 2011 Jan 12.
PMID 21228116
 
Written2011-01Geetha Srikrishna, Hudson H Freeze
Medical Research Institute, 10905 Road to the Cure, San Diego, CA 92121, USA

Citation

This paper should be referenced as such :
Srikrishna, G ; Freeze, HH
S100 Protein Family, Tumorigenesis
Atlas Genet Cytogenet Oncol Haematol. 2011;15(9):768-776.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/S100ProtFamilyTumorID20092.htm

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Sep 14 17:07:03 CEST 2016


Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.